Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Rumi

Showing results (1-10 of 184) with videos related to

Pageof 19
Sort By:
Hematological Oncology|May 20, 2008
Familial chronic myeloproliferative disorders: the state of the artElisa Rumi
Blood|August 27, 2016
How I treat essential thrombocythemiaElisa Rumi, Mario Cazzola
Blood|May 25, 2019
JAK inhibitors and risk of B-cell lymphomasElisa Rumi, Silvia Zibellini
The New England Journal of Medicine|March 19, 2020
Essential ThrombocythemiaElisa Rumi, Mario Cazzola
British Journal of Haematology|April 27, 2017
Advances in understanding the pathogenesis of familial myeloproliferative neoplasmsElisa Rumi, Mario Cazzola
Blood|December 29, 2016
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasmsElisa Rumi, Mario Cazzola
The New England Journal of Medicine|April 2, 2025
Clearance of Driver Mutations in MyelofibrosisElisa Rumi, Oscar Borsani
Haematologica|January 2, 2009
Clinical relevance of JAK2 (V617F) mutant allele burdenFrancesco Passamonti, Elisa Rumi
American Journal of Hematology|November 14, 2008
Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosisMelanie J Percy, Elisa Rumi
The New England Journal of Medicine|August 23, 2023
Primary Budd-Chiari SyndromeOscar Borsani, Daniela Pietra, Elisa Rumi
Pageof 19

Showing results (1-10 of 184) with videos related to

Sort By:
Pageof 19
Hematological Oncology|May 20, 2008
Familial chronic myeloproliferative disorders: the state of the artElisa Rumi
Blood|August 27, 2016
How I treat essential thrombocythemiaElisa Rumi, Mario Cazzola
Blood|May 25, 2019
JAK inhibitors and risk of B-cell lymphomasElisa Rumi, Silvia Zibellini
The New England Journal of Medicine|March 19, 2020
Essential ThrombocythemiaElisa Rumi, Mario Cazzola
British Journal of Haematology|April 27, 2017
Advances in understanding the pathogenesis of familial myeloproliferative neoplasmsElisa Rumi, Mario Cazzola
Blood|December 29, 2016
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasmsElisa Rumi, Mario Cazzola
The New England Journal of Medicine|April 2, 2025
Clearance of Driver Mutations in MyelofibrosisElisa Rumi, Oscar Borsani
Haematologica|January 2, 2009
Clinical relevance of JAK2 (V617F) mutant allele burdenFrancesco Passamonti, Elisa Rumi
American Journal of Hematology|November 14, 2008
Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosisMelanie J Percy, Elisa Rumi
The New England Journal of Medicine|August 23, 2023
Primary Budd-Chiari SyndromeOscar Borsani, Daniela Pietra, Elisa Rumi
Pageof 19